%0 Journal Article
%A Martinón-Torres, Federico
%A Halperin, Scott A
%A Nolan, Terry
%A Tapiéro, Bruce
%A Perrett, Kirsten P
%A de la Cueva, Ignacio Salamanca
%A García-Sicilia, José
%A Stranak, Zbynek
%A Vanderkooi, Otto G
%A Kosina, Pavel
%A Rumlarova, Sarka
%A Virta, Miia
%A Arribas, Jose M Merino
%A Miranda-Valdivieso, Mariano
%A Novas, Begoña Arias
%A Bozensky, Jan
%A Ortega, María José Cilleruelo
%A Amador, Jose Tomas Ramos
%A Baca, Manuel
%A Palomino, Esperanza Escribano
%A Zuccotti, Gian Vincenzo
%A Janota, Jan
%A Marchisio, Paola Giovanna
%A Kostanyan, Lusine
%A Meyer, Nadia
%A Ceregido, Maria Angeles
%A Cheuvart, Brigitte
%A Kuriyakose, Sherine O
%A Mesaros, Narcisa
%T Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
%D 2021
%U http://hdl.handle.net/10668/17210
%X Transplacentally transferred antibodies induced by maternal pertussis vaccination interfere with infant immune responses to pertussis primary vaccination. We evaluated whether this interference remains in toddlers after booster vaccination. In a prior phase IV, observer-blind, placebo-controlled, randomized study (NCT02377349), pregnant women in Australia, Canada and Europe received intramuscular tetanus-reduced-antigen-content diphtheria-three-component acellular pertussis vaccine (Tdap group) or placebo (control group) at 270/7-366/7 weeks' gestation, with crossover immunization postpartum. Their infants were primed (study NCT02422264) and boosted (at 11-18 months; current study NCT02853929) with diphtheria-tetanus-three-component acellular pertussis-hepatitis B virus-inactivated poliovirus/Haemophilus influenzae type b vaccine (DTaP-HepB-IPV/Hib) and 13-valent pneumococcal conjugate vaccine. Immunogenicity before and after booster vaccination, and reactogenicity and safety of the booster were evaluated descriptively. 263 (Tdap group) and 277 (control group) toddlers received a DTaP-HepB-IPV/Hib booster. Pre-booster vaccination, observed geometric mean concentrations (GMCs) for the three pertussis antigens and diphtheria were 1.4-1.5-fold higher in controls than in the Tdap group. No differences were observed for the other DTaP-HepB-IPV/Hib antigens. One month post-booster vaccination, booster response rates for pertussis antigens were ≥ 92.1% and seroprotection rates for the other DTaP-HepB-IPV/Hib antigens were ≥ 99.2% in both groups (primary objective). Higher post-booster GMCs were observed in controls versus the Tdap group for anti-filamentous hemagglutinin (1.2-fold), anti-pertussis toxoid (1.5-fold) and anti-diphtheria (1.4-fold). GMCs for the other DTaP-HepB-IPV/Hib antigens were similar between groups. Serious adverse events were reported for three toddlers (controls, not vaccination-related). One death occurred pre-booster (Tdap group, not vaccination-related). As a consequence of interference of maternal pertussis antibodies with infant immune responses to pertussis primary vaccination, pertussis antibody concentrations were still lower in toddlers from Tdap-vaccinated mothers before DTaP-HepB-IPV/Hib booster vaccination. After the booster, antibody concentrations were lower for filamentous hemagglutinin and pertussis toxoid but not for pertactin. The clinical significance of this interference requires further evaluation. ClinicalTrials.gov: NCT02853929.
%K Blunting
%K Booster
%K Maternal immunization
%K Pertussis
%K Tdap vaccine
%K Toddlers
%~